Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EBIT: 2016-2024

Historic EBIT for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$487.3 million.

  • Denali Therapeutics' EBIT rose 2.06% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 147.76%. This contributed to the annual value of -$487.3 million for FY2024, which is 147.76% down from last year.
  • Latest data reveals that Denali Therapeutics reported EBIT of -$487.3 million as of FY2024, which was down 147.76% from -$196.7 million recorded in FY2023.
  • Denali Therapeutics' 5-year EBIT high stood at $62.7 million for FY2020, and its period low was -$487.3 million during FY2024.
  • Its 3-year average for EBIT is -$341.6 million, with a median of -$340.7 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first spiked by 129.42% in 2020, then slumped by 571.56% in 2021.
  • Over the past 5 years, Denali Therapeutics' EBIT (Yearly) stood at $62.7 million in 2020, then plummeted by 571.56% to -$295.8 million in 2021, then decreased by 15.21% to -$340.7 million in 2022, then spiked by 42.27% to -$196.7 million in 2023, then plummeted by 147.76% to -$487.3 million in 2024.